LAB
Standard Biotools Inc
NASDAQ: LAB · HEALTHCARE · MEDICAL DEVICES
$0.93
+4.69% today
Updated 2026-04-30
Market cap
$350.48M
P/E ratio
—
P/S ratio
4.11x
EPS (TTM)
$-0.15
Dividend yield
—
52W range
$1 – $2
Volume
2.7M
Standard Biotools Inc (LAB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-87.80%
Operating margin
-92.10%
ROE
-13.10%
ROA
-9.88%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $6.40M | $-23.55M | 56.66% | -338.59% | -368.13% |
| 2007 | $7.28M | $-25.45M | 51.70% | -323.38% | -349.84% |
| 2008 | $15.35M | $-29.50M | 45.50% | -192.50% | -192.21% |
| 2009 | $25.41M | $-19.13M | 54.80% | -70.98% | -75.27% |
| 2010 | $33.56M | $-16.90M | 65.49% | -43.42% | -50.36% |
| 2011 | $42.87M | $-22.47M | 69.23% | -43.31% | -52.42% |
| 2012 | $52.33M | $-19.02M | 70.72% | -34.53% | -36.35% |
| 2013 | $71.18M | $-15.82M | 71.79% | -25.22% | -22.23% |
| 2014 | $116.46M | $-52.83M | 63.21% | -44.51% | -45.36% |
| 2015 | $114.71M | $-53.31M | 59.35% | -43.72% | -46.48% |
| 2016 | $104.45M | $-75.98M | 55.95% | -70.07% | -72.75% |
| 2017 | $101.94M | $-60.53M | 50.99% | -57.25% | -59.38% |
| 2018 | $112.96M | $-59.01M | 54.57% | -42.64% | -52.24% |
| 2019 | $117.24M | $-64.79M | 54.83% | -44.22% | -55.26% |
| 2020 | $138.14M | $-53.02M | 60.32% | -36.94% | -38.38% |
| 2021 | $130.58M | $-59.24M | 59.17% | -51.66% | -45.36% |
| 2022 | $97.95M | $-190.10M | 37.83% | -118.64% | -194.08% |
| 2023 | $106.34M | $-74.66M | 47.44% | -72.03% | -70.21% |
| 2024 | $174.43M | $-138.88M | 48.31% | -100.46% | -79.62% |
| 2025 | $85.33M | $-74.90M | 49.86% | -109.34% | -87.77% |